Show simple item record

dc.contributor.authorMelas, Ioannis N.
dc.contributor.authorLauffenburger, Douglas A.
dc.contributor.authorAlexopoulos, Leonidas G.
dc.date.accessioned2015-10-29T13:44:38Z
dc.date.available2015-10-29T13:44:38Z
dc.date.issued2013-11
dc.identifier.isbn978-1-4799-3163-7
dc.identifier.urihttp://hdl.handle.net/1721.1/99495
dc.description.abstractHepatocellular Carcinoma (HCC) is one of the leading causes of death worldwide, with only a handful of treatments effective in unresectable HCC. Most of the clinical trials for HCC using new generation interventions (drug-targeted therapies) have poor efficacy whereas just a few of them show some promising clinical outcomes [1]. This is amongst the first studies where the mode of action of some of the compounds extensively used in clinical trials is interrogated on the phosphoproteomic level, in an attempt to build predictive models for clinical efficacy. Signaling data are combined with previously published gene expression and clinical data within a consistent framework that identifies drug effects on the phosphoproteomic level and translates them to the gene expression level. The interrogated drugs are then correlated with genes differentially expressed in normal versus tumor tissue, and genes predictive of patient survival. Although the number of clinical trial results considered is small, our approach shows potential for discerning signaling activities that may help predict drug efficacy for HCC.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant U54-CA119267)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant R01-CA96504)en_US
dc.language.isoen_US
dc.publisherInstitute of Electrical and Electronics Engineers (IEEE)en_US
dc.relation.isversionofhttp://dx.doi.org/10.1109/BIBE.2013.6701683en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alikeen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/en_US
dc.sourcePMCen_US
dc.titleIdentification of signaling pathways related to drug efficacy in hepatocellular carcinoma via integration of phosphoproteomic, genomic and clinical dataen_US
dc.typeArticleen_US
dc.identifier.citationMelas, Ioannis N., Douglas A. Lauffenburger, and Leonidas G. Alexopoulos. “Identification of Signaling Pathways Related to Drug Efficacy in Hepatocellular Carcinoma via Integration of Phosphoproteomic, Genomic and Clinical Data.” 13th IEEE International Conference on BioInformatics and BioEngineering (November 2013).en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.mitauthorLauffenburger, Douglas A.en_US
dc.relation.journalProceedings of the 13th IEEE International Conference on BioInformatics and BioEngineeringen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/ConferencePaperen_US
eprint.statushttp://purl.org/eprint/status/NonPeerRevieweden_US
dspace.orderedauthorsMelas, Ioannis N.; Lauffenburger, Douglas A.; Alexopoulos, Leonidas G.en_US
mit.licenseOPEN_ACCESS_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record